Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TusQ-D is a combination pharmaceutical product developed and marketed by Blue Cross Laboratories, primarily used for the symptomatic relief of dry cough and symptoms associated with the common cold or allergic rhinitis. It contains three active ingredients: dextromethorphan hydrobromide (a cough suppressant), phenylephrine hydrochloride (a nasal decongestant), and chlorpheniramine maleate (an antihistamine). Dextromethorphan acts on the cough center in the brain to elevate the cough threshold. Phenylephrine is a sympathomimetic amine that acts on alpha-adrenergic receptors to cause vasoconstriction in the nasal mucosa, reducing congestion. Chlorpheniramine blocks H1 histamine receptors, alleviating allergic symptoms like sneezing and watery eyes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextromethorphan + phenylephrine + chlorpheniramine.